10 Biggest Price Target Changes For Wednesday
Keybanc cut Alibaba Group Holding Limited (NYSE: BABA) price target from $275 to $270. Alibaba shares rose 0.5% to $212.60 in pre-market trading.
Stifel Upgrades ChemoCentryx to Buy, Raises Price Target to $31
Stifel analyst Dae Gon Ha upgrades ChemoCentryx (NASDAQ:CCXI) from Hold to Buy and raises the price target from $26 to $31.
Why This ChemoCentryx Analyst Is Bullish
H.C. Wainwright analysts remain bullish on ChemoCentryx, Inc. (NASDAQ: CCXI) following an amended new drug application for avacopan.
The ChemoCentryx Analyst: Edward White reaffirmed a Buy rating on shares of ChemoCentryx, Inc. with a $28 price target.
ChemoCentryx Stock Is Approaching A Key Level
ChemoCentryx Inc. (NASDAQ: CCXI) shares traded higher Tuesday after the company announced it filed an amendment to its New Drug Application for avacopan for the treatment of anti-neutrophil cytoplasmic yutoantibody associated vasculitis. The U.S.
ChemoCentryx Stock Jumps On Amendment In Avacopan Application, New Goal Date Of October 7
Following consultations with the FDA, ChemoCentryx Inc (NASDAQ:CCXI) filed an amendment to its marketing application seeking approval for avacopan to treat Anti-neutrophil…
ChemoCentryx Shares Tick Higher; Co Announces Filing Of Amendment To NDA Submission, Extension Of The PDUFA Review Period For Avacopan In Treatment Of ANCA-Associated Vasculitis
ChemoCentryx, Inc., (NASDAQ:CCXI), today announced that, following consultations with the U.S. Food and Drug Administration (FDA), it filed an amendment to its New Drug Application (NDA) for avacopan for the treatment of
Biotech Losers In 2021 That Could Bounce Big In The Second Half
Biotech stocks are tricky investment bets that require careful analysis and scrutiny. A stock that has fallen off a cliff in reaction to a binary event can neither be written off entirely nor picked as a bargain buy. A lot of background research should go into the stock, company pipeline, cash runway, and other factors before an investment decision can be made.
The Week Ahead In Biotech: Focus On Chemocentryx FDA Decision, Conference Presentations In A Light Week
Biotech stocks advanced for a second week in running, with stocks reacting to pending releases for the second quarter and the first-half of the year.
Attention Biotech Investors: Mark Your Calendar For July PDUFA Dates
June was a month of plenty and also turned out to be a fruitful one from the perspective of Food and Drug Administration approvals. Regulatory reviews mostly produced positive verdicts, and rejections or no-decisions were few and far between.
28 Stocks Moving in Friday’s Pre-Market Session
Gainers
Amesite Inc. (NASDAQ: AMST) rose 138% to $6.60 in pre-market trading after surging over 25% on Thursday.